The study results will be used to check the hypothesis that CareLink Express remote monitoring system increases the detection rate of asymptomatic AF and allows to change timely the treatment strategy in patients at high risk of thromboembolic events, e.g. anticoagulation therapy onset, electrical cardioversion or/and PVI.
It is expected to enroll 200 consecutive patients without previously diagnosed AF, who have indications for implantation of dual chamber cardiac pacemakers according to the current guidelines. All the patients will be randomly assigned into 2 groups. Patients in the RM group will undergo the implantation of Ensura DR MRI SureScan pacing system, whereas patients in the control group will receive ADAPTA DR pacing system without RM using. The impact of the Care Link Express service on prevention of thromboembolism will be evaluated. The rate of in-hospital visits for 1 patient per year and compliance with scheduled CareLink transmissions (ratio of the number of the performed transmissions to the planned ones) will be assessed in all patients in the remote monitoring group. Moreover, we are going to estimate the interaction between the follow-up center and other healthcare facilities equipped with the CareLink Express service, which will facilitate faster treatment decision.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
Research Institute for Complex Problems of Cardiovascular Diseases
Kemerovo, Russia
RECRUITINGtime (days) from the pacemaker system implantation to the first AF episode detected by ESG or EGM
the episode should be evaluated by the follow-up clinic physician(s) and meet the appropriate criteria (irregular RR intervals and distinct P waves, ≥30s episode duration)
Time frame: 24 months
thromboembolic events
Number of participants with ischaemic stroke, transient ischaemic attack and thromboembolism (including any arterial embolism and paradoxical embolism)
Time frame: 24 months
hospitalization for cardiovascular events
Number of participants with arrhythmia, heart failure decompensation, thromboembolic events
Time frame: 24 months
the number of non-planned induced visits in the follow-up center
Number of visits for 1 patient per year
Time frame: 24 months
correction in the medical therapy
Number of participants with antiarrhythmic therapy or/and oral anticoagulation therapy initiated after the AF detection
Time frame: 24 months
cardioversion
Number of patinents underwent electrical cardioversion
Time frame: 24 months
catheter/surgical PVI
Number of patients underwent catheter or surgical atrial fibrillation ablation
Time frame: 24 months
all-cause mortality
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of patients dead because of all causes
Time frame: 24 months